MAIA Biotechnology, Inc.
Wednesday, June 05, 2024
Company Presentation
![Oncology](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/BIO-track-icon_Oncology_MTC.png)
Company Presentation Theater 1
MAIA is an immuno-oncology company focused on the development and commercialization of potential first-in-class drugs that are intended to meaningfully improve and extend the lives of people with hard-to-treat cancers. We are exploring a new science for cancer therapy utilizing a novel dual mechanism of action: telomere targeting and immunogenicity. Our lead program is THIO, a first-in-class anticancer agent in clinical development for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients with telomerase-positive cancer cells.
![MAIA Biotechnology, Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1802730-1-JPG.png)
Company Website:
https://maiabiotech.com/
Lead Product in Development:
THIO
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Exchange
NYSE American
Ticker
MAIA
Company HQ City
Chicago
Company HQ State
Illinois
Company HQ Country
United States
CEO/Top Company Official
Vlad Vitoc
Development Phase of Primary Product
Phase II
Primary Speaker